Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib

The anti-diabetic drug metformin is currently tested for the treatment of hematological and solid cancers. Proteasome inhibitors, e.g., Bortezomib, are approved for the treatment of multiple myeloma and mantle cell lymphoma but are also studied for lung cancer therapy. We here analyzed the interacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlesser, Camille, Meul, Thomas, Stathopoulos, Georgios, Meiners, Silke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221333/
https://www.ncbi.nlm.nih.gov/pubmed/35740881
http://dx.doi.org/10.3390/biom12060756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221333/
https://www.ncbi.nlm.nih.gov/pubmed/35740881
http://dx.doi.org/10.3390/biom12060756

Ejemplares similares